Search

Displaying results 8141 - 8150 of 10000 in total
  1. Drug

    Dihydroquinidine barbiturate

    go.drugbank.com/drugs/DB01341
    Experimental

  2. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.

  3. Drug

    Levonadifloxacin

    go.drugbank.com/drugs/DB16219
    Investigational

    Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections

  4. Drug

    Ethylmercurithiosalicylic acid

    go.drugbank.com/drugs/DB02731
    Experimental

    Ethylmercurithiosalicylic acid is a topical antiseptic used on skin and mucous membranes. It is also used as a preservative in pharmaceuticals.

  5. Drug

    Lazuvapagon

    go.drugbank.com/drugs/DB19046
    Investigational

    Lazuvapagon is under investigation in clinical trial NCT03116191 (Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects).

  6. Drug

    ZUBERITAMAB

    go.drugbank.com/drugs/DB19443
    Investigational

    Zuberitamab is under investigation in clinical trial NCT06642909 (A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy).

  7. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection. … Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide.

  8. Drug

    Cefilavancin

    go.drugbank.com/drugs/DB05735
    Investigational

    Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.

  9. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential

  10. Drug

    MK-0752

    go.drugbank.com/drugs/DB12852
    Investigational

    Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).